Overview

• Rare disease company reported 2025 net product sales of $521 mln, up from 2024

• Company expects 2026 global net product sales of $630 mln to $650 mln

• Company completed acquisition of Bluejay Therapeutics, adding brelovitug for HDV

Outlook

• Mirum expects 2026 global net product sales of $630 mln to $650 mln

• Volixibat VISTAS study topline data expected in Q2 2026

• LIVMARLI EXPAND study topline data expected in Q4 2026

Result Drivers

• LIVMARLI SALES GROWTH - LIVMARLI net product sales increased 69% year-over-year in the U.S., contributing significantly to 2025 revenue growth

• GLOBAL EXPANSION - Expanded commercial access to 33 countries, enhancing global sales reach

• BLUEJAY ACQUISITION - Acquisition of Bluejay Therapeutics added brelovitug for HDV, enhancing pipeline

Company press release: ID:nBwc886mla

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $112.50, about 4.7% above its February 24 closing price of $107.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)